Medicare Part B Drugs With Discarded Units Above the 10% Threshold

Pharmaceuticals and Biotech Strategic Analytics, Value and Economics

Caitlin Sheetz, MPH
June 7, 2023

With the release of the Medicare Part B discarded units’ policy, the life sciences industry is seeking to better understand the shifting landscape and evaluate key impacts. The ADVI Strategic Analytics, Value and Economics (SAVEs) team has been analyzing Medicare claims data to assess specific drug-dosing patterns in both the outpatient hospital and physician office setting. This data, along with a 3-step plan has allowed ADVI’s clients to assess their approach for future CMS engagement and go-to-market strategies.

ADVI SAVEs 3-Step Discarded Units’ Quarterly Support Plan

ADVI continually works with clients using a 3-step plan to better understand the implications of the Medicare Part B discarded units’ policy. These steps include:

  1. Calculating discarded units’ percentages by products and by site of service (i.e., HOPD, office, etc.)
  2. Analyzing outpatient hospital and physician office billing practices for administered vs discarded units
  3. Estimating product-level liability based on CMS’ established 10 percent threshold
For a list of the Part B drugs with discarded units’ percentage over the 10 percent threshold, see our table here
(ADVI Health Analysis of 2021 vs 2022 Data Related to Part B Drug Discarded Units).

The SAVEs team will continue to provide clients with a first look at how the changes may impact their business. If you are interested in additional analysis related to Part B drug discarded units, or the Part B or Part D drug dashboards please get in touch.


Caitlin Sheetz, MPH
Senior Vice President and Head of Strategic Analytics, Value and Economics

CEO insights

Real analysis from people who’ve been there

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Uncategorized

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …

February 10, 2026

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act

Real-World Effectiveness vs Clinical Trial Efficacy in Medicare

The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …

October 1, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Pharmaceuticals and Biotech

ADVI Analysis: MACPAC October 2024 Meeting

MACPAC held a meeting on October 31 and November 1, 2024 (link). The following relevant topics were discussed: ADVI Angle …

November 11, 2024

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.